Heart failure with preserved ejection fraction (HFpEF) is a growing epidemiologic problem affecting more than half of the patients with heart failure (HF). HFpEF has a significant morbidity and mortality and so far no treatment has been clearly demonstrated to improve the outcomes in HFpEF, in contrast to the efficacy of treatment in heart failure with reduced ejection fraction (HFrEF).The fail...

BACKGROUND Mortality in heart failure (HF) remains high but causes of death are incompletely defined. As HF is heterogeneous syndrome categorized according to ejection fraction (EF), the association between EF and causes of death is important, yet elusive. METHOD AND RESULTS Community subjects with HF were classified according to preserved (> or =50%) and reduced EF (<50%). Deaths were classi...

BACKGROUND Acute heart failure (AHF) with its high in-hospital mortality is an increasing burden on healthcare systems worldwide, and comparing hospital performance is required for improving hospital management efficiency. However, it is difficult to distinguish patient severity from individual hospital care effects. The aim of this study was to develop a risk adjustment model to predict in-hos...

Background acute myocarditis (AM) clinical onset can span from subclinical disease to acute heart failure (AHF) ventricular fibrillation (VF) or sudden cardiac death in young adults. Myocarditis can underly the aetiology of other cardiomyopathies (CM) such as dilated CM arrhythmogenic left or right ventricle CM. Aim of the study was to evaluate the relationship between myocardial oedema and lat...

Nearly 40 years ago, recommendations to treat acute heart failure (AHF) included oxygen, diuretic agents, vasodilators, and inotropes (1). Although the addition of rotating tourniquets and phlebotomy have become historical footnotes, a clinician treating AHF today would essentially use the same therapeutic modalities. A layperson might conclude that significant reductions in morbidity and morta...

The quantitative and qualitative estimation of total body fluid content has proven to be crucial for both diagnosis and prognosis assessment in patients with heart failure. The aim of this review is to summarize the current techniques for assessing body hydration status as well as the principal biomarkers associated with acute heart failure (AHF). Although clinical history, physical examination...

The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure (AHF). Secondary objectives were signals efficacy, including biomarkers, symptoms, and clinical events. Nitroxyl (HNO) donors have vasodilator, inotropic lusitropic effects. Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for This a phase IIb, double-blind, randomiz...